Imatinib Denk (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases. This inhibition prevents downstream phosphorylation events that normally promote cell division and survival, leading to apoptosis of cancer cells that rely on these signaling pathways.

The dosage of Imatinib Denk is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, and renal or hepatic function. Only a qualified healthcare professional can determine the appropriate regimen.

Imatinib is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imatinib was the first approved BCR‑ABL inhibitor and remains a standard first‑line option for chronic phase CML. Newer agents such as dasatinib or nilotinib may be used for resistant disease or specific patient profiles, but Imatinib offers a well‑characterized safety and efficacy record.

Imatinib Denk should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources to maintain product stability.

Imatinib Denk is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare provider to ensure consistent absorption.

Serious risks include hepatotoxicity, severe neutropenia, and cardiotoxicity such as heart failure. Patients should be monitored regularly for liver enzyme elevations, blood counts, and cardiac function, and any concerning symptoms should be reported promptly.

Imatinib Denk is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in pregnant women unless absolutely necessary, and caution is advised for individuals with severe hepatic impairment or uncontrolled cardiac disease.